Cited 0 times in
Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Non-Small Cell Lung Cancer: TATTON
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.